PolarDoc CEO Jenny Pei discusses PPRIM imaging device for preterm birth risk assessment
Summary
JunZhu (Jenny) Pei, CEO of PolarDoc, introduces PPRIM, a handheld device using polarized light to analyze cervical collagen structure for preterm birth risk. She contrasts this with current ultrasound and manual methods, claiming superior accuracy by targeting underlying tissue mechanics. The company is preparing for broader clinical trials and pursuing FDA approval, aiming to shift care from reactive to preventative. Pei outlines a hardware-adjacent SaaS business model targeting a global market of 1.5 billion, with AI reserved for future complex case handling.
Key takeaways
- 1 Yes. So every 40 seconds, a child dies from being born too early, and every two seconds a child is born too early.
Unidentified speaker (speaker_2) · 2:33
Episode sections
- 0:26 – 2:30
Introduction and Company Origin
Ray Crowley introduces JunZhu (Jenny) Pei, CEO of PolarDoc, a private venture developing portable preterm imaging technology. Pei explains the company's origin stems from her PhD advisor's personal difficulty conceiving and the medical gap in identifying preterm labor risks.
- 2:30 – 4:51
Problem Statement and Technology Overview
Pei highlights that every 40 seconds a child dies from being born too early, with no current method to identify risk before labor begins. The solution is PPRIM, a handheld imaging device using polarized light to capture cervix images, which software analyzes to determine tissue stiffness and preterm risk.
- 4:51 – 5:56
Competitive Landscape and Accuracy
Pei contrasts PolarDoc with European suction-based stiffness tests and current hospital practices like ultrasound or manual palpation, which she claims are inaccurate. She asserts PPRIM is more accurate because it analyzes the underlying collagen structure mechanism rather than just surface touch or length.
- 5:56 – 6:46
Validation Status and Clinical Trials
The company has completed animal studies in mice and human pilots comparing pregnant and non-pregnant cervices. Pei states they are preparing for a broader clinical trial to optimize software for diverse populations and medical conditions.
- 6:46 – 7:18
Regulatory Path and Funding
Pei confirms the company is pursuing FDA approval, describing the process as long and intense. She notes they are currently raising money to fund this regulatory pathway.
- 7:18 – 8:48
Market Size and Go-to-Market Strategy
Pei cites a beachhead market of 33 million in Florida, a serviceable market of 540 million, and a global market of 1.5 billion. The strategy involves partnering with hospitals like Baptist Hospital in South Florida, offering cameras at a discount and generating revenue via software subscriptions and disposable camera covers.
- 8:48 – 10:41
Role of AI in the Technology
Pei clarifies that the core analysis of collagen fiber orientation uses physics, not AI. AI is intended for future implementation to handle complex cases, such as identifying scarring from cervical cancer, to ensure accurate tracking during pregnancy.
- 10:41 – 14:08
Milestones and Vision
The primary 12-month goal is completing the clinical trial and obtaining FDA approval. Pei envisions a future where early detection allows for less aggressive interventions like cervical cerclage, shifting care from reactive to preventative.
Claims worth verifying
Every 40 seconds, a child dies from being born too early, and every two seconds a child is born too early.
Unidentified speaker (speaker_2) ·2:33
How to verify: CDC National Center for Health Statistics data on infant mortality and preterm birth rates; WHO global preterm birth reports. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
PPRIM uses polarized light to identify specific portions of tissue related to strength.
Unidentified speaker (speaker_2) ·1:39
How to verify: Patent filings for PPRIM technology at USPTO or WIPO; peer-reviewed publications by Dr. Jessica Ramella-Roman on polarization optics for tissue analysis. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Primary sourceEuropean technology uses a suction system to test tissue stiffness by touch.
Unidentified speaker (speaker_2) ·5:18
How to verify: Medical literature search for cervical stiffness testing devices using suction or aspiration; FDA database for cleared devices in Europe. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
The global market for preterm birth risk imaging is estimated to be 1.5 billion.
Unidentified speaker (speaker_2) ·7:38
How to verify: Market research reports on maternal health diagnostics; healthcare spending data on preterm birth complications from WHO or CDC. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Baptist Hospital is the biggest hospital system in South Florida.
Unidentified speaker (speaker_2) ·7:58
How to verify: Hospital system rankings by bed count or revenue in South Florida; Baptist Health South Florida official website or annual reports. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
PolarDoc was one of eight global finalists in the 2026 EF Hult Prize from a field of 18,000 startups.
Unidentified speaker (speaker_2) ·11:43
How to verify: EF Hult Prize official website archives for 2026 finalists; press releases from FIU or PolarDoc regarding the award. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Cervical cerclage is a simple procedure that can help ensure a full-term pregnancy if done early.
Unidentified speaker (speaker_2) ·12:27
How to verify: Clinical studies on cervical cerclage efficacy; ACOG (American College of Obstetricians and Gynecologists) guidelines on preterm birth prevention. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
The core analysis of collagen fiber orientation uses physics, not AI.
Unidentified speaker (speaker_2) ·9:25
How to verify: Technical documentation or white papers from PolarDoc describing the PPRIM algorithm; patents detailing the image processing steps. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the statistic 'every 40 seconds a child dies from being born too early' against WHO or CDC global mortality data.
- Review FDA regulatory pathways for Class II or Class III medical devices to assess the timeline and cost of approval.
- Analyze the competitive landscape for cervical stiffness testing, including European suction-based tests and ultrasound metrics.
- Check PolarDoc's clinical trial registration status on ClinicalTrials.gov for the 'broader clinical trial' mentioned.
- Evaluate the accuracy claims of PPRIM against peer-reviewed studies on collagen structure analysis versus ultrasound length measurements.
- Assess the sustainability of the hardware-adjacent SaaS model by comparing it to existing hospital procurement and subscription models.
- Confirm the 2026 EF Hult Prize finalist list to verify the startup's selection from 18,000 teams.
- Investigate the specific medical conditions and populations included in the 'diverse populations' clinical trial optimization.
Full transcriptexpand
0:00Unidentified speaker (speaker_0): You are now dialed into Investment Research Radio. All material on this program is not to be taken as investment advice and is for informational purposes only. Investment Research Radio interviews the most exciting up-and-coming companies as well as market commentary from leading analysts and traders. Now with your host, Ray Crowley.
0:26Ray Crowley: Welcome to Investment Research Radio. I'm your host, Ray Crowley. Today we have Jun Shu Pei, also known as Jenny, co-founder and CEO of Polar Doc, which is a private venture developing uh prim technology, which is in the world of portable preterm imaging. Welcome on to the podcast today, Jenny.
0:49Unidentified speaker (UNKNOWN): Thank
0:50Unidentified speaker (speaker_2): you, Ray.
0:51Ray Crowley: Tell us about Polar Doc and this the original story behind it and how you got involved.
0:58Unidentified speaker (speaker_2): Well, the original story behind Polar Doc was actually from my um current advisor for my PhD in my last year, but she had some difficulties um get conceiving because she's um a little bit older. And so she realized that there was a lot of there's a huge gap in, you know, the medical field in identifying risks for women who could go into preterm labor. And so with her knowledge in optics, she decided to kind of fill that gap and began testing a system with polarization optics, which is the type of so it uses polarization, which is what our poli eye sunglasses block from the sunlight. And it uses that to actually identify specific portions of the tissue that can
1:59then be related into the strength of the particular tissue. And so she kind of started that venture and they've done a lot of, you know, clinical pilots as well as animal studies and built out a whole system. And I come in with the validation and the clinical trial process for my PhD.
2:26Ray Crowley: So what is the main problem that you're solving? It's in the world of premature birth. Is that correct?
2:33Unidentified speaker (speaker_2): Yes. So every 40 seconds, a child dies from being born too early, and every two seconds a child is born too early. So this is a very big issue in the world. And there isn't really anything to identify a woman's risk of having this problem. Um, the only way that it's normally identified is if she already had a preterm birth, or if um her or sorry, so if she already had a preterm birth, or it they have like devices that can tell you that she's basically about to go into preterm labor in the next week. But anything before that, there's really not anything available. And so we aim to fill that gap.
3:20Ray Crowley: And what does the technology look like? Is it a device paired with software?
3:27Unidentified speaker (speaker_2): Yes, it is an imaging device. It's basically a um,
3:31Unidentified speaker (UNKNOWN): yeah,
3:32Unidentified speaker (speaker_2): it's an imaging device to look at the cervix, which is the portion of the um woman that holds the baby in place during pregnancy. And then there's a software that identifies like the stiffness of this tissue, and that's how we can identify whether the woman is at risk for delivering too early.
3:56Ray Crowley: Tell us about the technology. It's called PRIM, it's got an acronym PPR. PPRIM.
4:04Unidentified speaker (speaker_2): Yes. So the PPRIM stands for Portable Preterm Imaging. And it's basically the system, the whole system. And so it has a camera that is inserted through the vaginal canal to take a picture of the cervix. And then we have a software that then I analyzes that image and then identifies the stiffness of the cervix through. that an analysis. And we also have a disposable camera cover that allows for the woman to take the image themselves. Um, of course, we will be rolling out specifically in hospitals right now, but in the far future we do hope to uh move into telemedicine.
4:45Ray Crowley: What makes it different? Um like I think you mentioned that there really isn't much out there. in terms of preventative or diagnostic care in the space.
4:58Unidentified speaker (speaker_2): Especially in the um the Americas, there is a technology in Europe that uses a suction system to kind of test the stiffness of the tissue by touch um by touching it, basically. We do it by imaging and right now, though, in actual clinics or in the hospital, physicians tend to use their fingers to either feel the cervix or image with an ultrasound to look at how long the cervix is and kind of refer from that. Infer from that. But it's not always accurate. And so we are looking at the actual um underlying. mechanism as to what causes the cervix to break down too early. And so it's more um accurate and a better assessment of preterm birth risk.
5:50Unidentified speaker (UNKNOWN): So
5:51Ray Crowley: how much research and validation has been accomplished to date?
5:56Unidentified speaker (speaker_2): Well, there has been um animal studies in mice where the cervix is relatively similar to humans to look at if we are able to track gestation with what we're with our technology. And there has also been human pilots looking at whether or not we can identify, you know, the non pregnant versus pregnant cervix. And so our new um clinical trial that we will be, you know, implementing soon would be to obtain a much broader data set so that we can look at women who have different medical conditions or are of a diverse population so that we can optimize our software to identify risk for them.
6:40Ray Crowley: Do you have a regulatory and clinical development pathway set up? That
6:46Unidentified speaker (speaker_2): Yes, we will be going through the uh FDA process. It's um relatively long and intense, and that is where we're currently raising our money for. Yes.
6:59Unidentified speaker (UNKNOWN): You
7:00Ray Crowley: mentioned
7:01Unidentified speaker (UNKNOWN): the
7:01Ray Crowley: a little bit of statistics earlier.
7:03Unidentified speaker (UNKNOWN): Uh,
7:04Ray Crowley: what's the market opportunity here? And how do you envision that um initial market? And
7:10Unidentified speaker (UNKNOWN): I
7:11Ray Crowley: guess you've also mentioned hospitals. So
7:13Unidentified speaker (UNKNOWN): um
7:14Ray Crowley: if you could just speak on the market opportunities uh on this.
7:18Unidentified speaker (speaker_2): Yes. So our beachhead market is here in Florida and so that's about 33 million. Um our serviceable market is about five hundred and forty million and the global market right now is estimated to be one point five billion. But right now there isn't any type of imaging s for preterm birth risk. So we see this all the market sizes growing. And also how we will, you know, roll out our technology would be through our clinical partners. So right now we are in talks with Baptist. So as um at we might mention this in the future, but this is a startup coming out of Florida International University, and we already have a relationship with Baptist Hospital, which is the biggest hospital. system down here in South Florida. And so we were able to um build a relatively strong connection with them. And so with the CEO and the OBGYN medical director, we are hoping to roll out a clinical trial, and that will then also allow our system to be deployed in the hospital. And so that's where we would start Um, because we have the actual camera, but then we have a soft uh subscription for the software as well as the camera covers that are disposable. And so the you know, the
8:37cameras would be, you know, provided to them at a heavily discounted rate, but then the subscriptions will, you know, start our revenue process, and then we hope to roll that to uh additional hospitals from
8:47Unidentified speaker (UNKNOWN): there. If We
8:48Ray Crowley: could revisit back to the technology itself, um, I'm assuming there's probably an AI equation in this, and that you probably have your own AI models. Is that uh an element to this technology?
9:05Unidentified speaker (speaker_2): It's a relatively small um element. Um AI, of course, is everywhere now, and we definitely would like to implement it, but it's not specifically for. the analysis portion. Um, so what we do is we can see collagen fiber orientation with polarization light. So this is well established, you know, we're able to already see that without any additional analysis of the image. And so we can then take the image and analyze. how the fibers are changing throughout the cervix, and if they're changing to a lot, then that means that they're very disorganized, and disorganized fibers then lead to a much softer cervix because you know it's not there to kind of hold it in place, and that is what we use to then identify a woman's wrist, and so that portion does not use AI, that portion. is, you know, just physics. But
10:05we do hope to then implement AI for different conditions that a woman might have. For example, if she already has scarring there from cervical cancer, then we would be able to kind of identify that area as something we wouldn't want to look into and track it throughout her gestational um her, you know, pregnancy, because we hope to implement this in the standard of care. so that woman would be imaged every time she goes to a prenatal visit. And so that's where the AI would come in. But it doesn't actually like it's not as involved in the other processes.
10:40Unidentified speaker (UNKNOWN): So
10:41Ray Crowley: what are your biggest uh priorities and goals of the next twelve 12 months and beyond and your biggest milestones that you're looking to accomplish? in the near to midterm?
10:53Unidentified speaker (speaker_2): Well, yeah, our biggest milestone is definitely to get our clinical trial, you know, completed and also get our FDA approval. So once we are able to get that, then you know, we're off to the races. This is a very intense uh hurdle though for just medical devices in general. And so we we're are definitely in the process of raising money for
11:13Unidentified speaker (UNKNOWN): that.
11:15Ray Crowley: You wanna you won a entrepreneurial prize competition. Could you touch on the the Holt prize?
11:23Unidentified speaker (speaker_2): Oh, yes. So I actually did send you the link for this prize. It's the it's called the um nickname the Nobel Prize for Students. And it's the biggest um startup competition for students around the world. And so we were uh eight of the global finalists for this competition. And so it's comes from over, I think, eighteen thousand startup teams around the world. And so we're very proud to be able to, you know, represent Florida International University in this competition and go so far.
11:57Ray Crowley: Excellent. So what's the big vision for the company looking ahead? five or ten years, uh, what would you like to see Polar Doc accomplish?
12:09Unidentified speaker (UNKNOWN): Well,
12:09Unidentified speaker (speaker_2): I hope that we are able to then um be deployed in hospitals to help physicians identify the a woman's risk. Right now, if a woman's um is able to be identified early, there's a simple procedure that can be done to help her, you know, have a full-term pregnancy. But this is this has to be done relatively early, and it's a stitch called a circlage um above the cervix. Um, it's actually abdominal circlage, which is the most successful one. But there's not additional interventions that are as you know successful because it doesn't tend to be identified this early. Physicians tend to deal with preterm birth like um. you know, as a consequence. So they see the problem happening and then they deal with, you know, the issues that come with it. But we believe that if we have a better understanding of this process, we can then identify different interventions early that can then be, you know, less aggressive
13:11and just as successful for preventing this pros problem.
13:18Ray Crowley: Well thank you so much for coming on to investment research radio. I'm really excited for Polar Doc. I think it's a very unique and needed technology. How can listeners either get a hold of you or find out more information?
13:34Unidentified speaker (speaker_2): Oh well I would love for them to connect with me on LinkedIn. Um, we also have our um website that I can leave with you um and for our progress in the next couple of years.
13:50Ray Crowley: Really looking forward to watching you guys cross those milestones and advance uh into FDA approval in the future. Thanks for coming on here.
14:00Unidentified speaker (speaker_2): Thanks so much.